
RDPlatform

Research activities in Europe: Trends and determinants



Rare Disease Day Brussels, 1 March 2010



RDPlatform Goals

RDPlatform is a FP7 project :

- To provide an overview of the ongoing research on rare diseases in Europe
- To give access to the information on on-going research activities in 25 countries via Orphanet
- To identify new avenues for research
- To describe research infrastructures specific to the RD research
- To provide recommendations to target calls for proposals at the EC and member state level


orphanet



Research in the field of RD: where to we stand?


- 4 770 ongoing research projects, excluding clinical trials
 - Covering 2121 diseases
 - 524 Gene search
 - 701 Mutation search
 - 255 Gene expression profile
 - 346 Animal model creation/study
 - 353 Genotype/phenotype correlation
 - 89 Biomarker development
 - 313 Diagnostic tool/protocol development
 - 228 Epidemiological studies
 - 174 Observational clinical studies
 - 57 Preclinical cell therapy
 - 121 Preclinical gene therapy
 - 128 Preclinical drug therapy

Distribution of number of diseases by number of basic research projects






Distribution of number of diseases by number of pre-clinical and epidemiological research projects








Number of research projects by disease classed by prevalence




Number of projects by disease by prevalence range










Major progresses in gene identification translating into diagnostic tests







R&D in the field of RD: where do we stand?

- Potential products in development : Orphan designations as a proxy
 - 581 orphan designations
 - for potentially treating 343 diseases
 - affecting 8.2 Million people
- Products in development: On-going clinical trials
 - 666 ongoing unique trials
 - for potentially 312 diseases
 - affecting 6.8 Million people
- Products on the market:
 - 99 marketed drugs for treating 141 diseases
 - √ 55 drugs with MA and OD in Europe for 82 diseases
 - √ 44 drugs with MA but no OD for 74 diseases

Trends in Orphan Designations



581 Orphan designations are concentrated on 343 rare diseases






List of non-tumours RD with over 3 orphan designations

Cystic Fibrosis	30	Pulmonary fibrosis, idiopathic	5 5
Pulm. Art. hypertension	13	Retinitis pigmentosa	5
Chronic pulm. hypertension	11	Sickle cell anaemia	5
Graft versus host disease	9	Tuberculosis	5
Acute respiratory distress	7	Beta-thalassemia	4
Amyotrophic lateral sclerosis	s 7	Haematopoietic cell transpl.	4
Spinal cord injury	7	Duchenne musc. dystrophy	4
Alpha-1 antitrypsin deficienc	y 6	Rejection corneal transplant.	4
		Scleroderma	4

Trends in Clinical Trials



666 ongoing national or international unique clinical trials for 312 diseases




Rare Disease with the highest number of clinical trials in Europe

Leukemia, myeloid, acute	45	Hodgkin lymphoma, classical	17
Leukemia, lymphoblastic, acute	34	Myeloma, multiple	17
Glioblastoma	32	Friedreich ataxia	16
Myelodysplastic syndromes	28	Mantle cell lymphoma	16
Cystic fibrosis	27	Ependymoma	14
Atypical hemolytic uremic syndrome	26	Leukemia, B-cell lymphocytic, chronic	14
Diffuse large B-cell lymphoma	20	Pulmonary fibrosis, idiopathic	14
Chronic myeloid leukemia	19	Follicular lymphoma	13
Astrocytoma	17	Leukemia, promyelocytic, acute	13
Graft versus host disease	17	Amyotrophic lateral sclerosis	12

www.orpha.net


% of diseases by medical area with at least one product in development (OD &CT)





Drug therapy: R&D by Medical Area Number of products in development or with MA

Solid tumors	173		Ophthalmology	20
Neurology	151		Bone diseases	17
Haematology	118		Malformations	13
Metabolism	68		Gynecology	13
Dermatology	59		Psychiatry	13
Endocrinology	51		Hepatology	13
Rheumatology	38		Cardiology	10
Immunology	35		Vascular diseases	9
Infectiology	33		Intoxications	7
Gastroenterology	32		Allergology	6
Nephrology	27		Urology	2
Pneumology	23	•	Maxillofacial	2



Possible Determinants




395 Registries as strategic tools Number of patient registries per country


France	103	Ireland	9
Germany	51	Portugal	7
Great-Britain	50	Switzerland	6
Italy	47	Greece	2
Spain	28	Bulgaria	4
Belgium	19	Denmark	3
Netherlands	10	Romania	2
Austria	13		

 Orphanet Report Series on Orphanet front page

orphanet

Characteristics of Registries





orphanet


60 International Patient Registries Around a medicinal product

- Cystic fibrosis
- Alpha 1 anti-trypsin
- Bleeding disorders
- Langerhans cell histiocytosis
- Severe chronic neutropenia
- Biliary atresia
- Neuromuscular diseases
- Wilson disease

- Fanconi anemia
- Pulmonary hypertension
- Metabolic diseases:
 Gaucher, Fabry,
 Pompe, MPS1...
- Ondine syndrome
- Primary immunodeficiencies
- Retinal dystrophies
- Huntington disease

Distribution of number of diseases covered by 1859 patient organisations (1 667 diseases)

Most represented: Cystic Fibrosis, neuro-muscular diseases, Fra X, Prader-Willi, Haemophilia, Turner, Scleroderma, Williams, Osteogenesis imperfecta, Marfan....





Conclusion

- No totally neglected areas
- No clue = no research
- Basic research goes on independantly from prevalence
- Major achievements in gene identification translating into tests
- Development in traditional areas for drug therapy +
 Additional Innovative approach with gene and cell therapy
- Registries, European networks and patient organisations are determinants of R&D
- Research requires a community of interested-parties to reach the critical mass

orphanet

Conclusion


- Disease-specific factors associated with Drug development (Drug Discovery Today Oct 2009 by Heemstra et al.)
- Prevalence: significant difference for > and < to 1 in 10,000</p>
- Disease class: traditional classes as research is a process
- Disease-specific scientific output:
 - ✓ Diseases with more than 600 published papers have twofold higher likelihood to have a product compared to diseases with 200 papers

Conclusion (2)

- Need for Public funding for:
 - To go from hypothesis to proof of concept and first clinical evidence
 - To establish and maintain registries
 - To run academic clinical trials for orphan indications
 - To run protocol trials
- Need for public/private partnership for Registries
- Need to bridge the gap between basic research and clinical research
 - develop databases, information systems, biobanks in general
 - Invest on Web 3.0, the semantic web
- Need to regularly organise surveys about possible valuable hypothesis, not tested for reasons possible to address



Many facilities to retrieve information on research activities, clinical trials and orphan drugs



RARE DISEASES

- Information about a disease
- Alphabetical list
- Search by clinical sign
- Search by gene
- Emergency guidelines
- Encyclopaedia for patients
- Encyclopaedia for professionals
- Classifications
- About Rare Diseases
- Prevalence of Rare Diseases

Improve the quality of medical care for Rare Diseases.


Provide adapted services for the rare disease community


About Orphanet | Quality charter Register your activity


Languages : Français | English | Español | Deutsch | Italiano












orpnanet







The portal for rare diseases and orphan drugs

Rare diseases Orphan drugs Clinics Diagnostic tests

Research and trials Patient organisations Directory of resources

Other information

Search

List Of Orphan Designations List Of Orphan Drugs with MA

List Of Substances **List Of Drugs**

Register / Update your activity

Homepage » Orphan drugs » Search

Sélectionner une langue 🕶

Print

Fourni par Google™Traduire

SEARCH BY SUBSTANCE/TRADENAME

imatinib

Substance / Tradename

→ ок

OTHER SEARCH OPTION(S)

- > Search by disease name
- > Search by ATC category
- > Search by Sponsor / MA holder

:: Orphan designation - Europe

Substance:

Summary of

Opinion [4]

(*) mandatory field

Imatinib mesilate

ATC code:

Orpha number: ORP

ORPHA133706

EU Number : Designation date

ate 1

EU/3/01/021 14/02/2001

:

Sponsor of orphan

designation :

NOVARTIS EUROPHARM LIMITED

Diseases list

▶ Chronic myeloid leukemia

Additional information

Orphanet Reports series

- > Prevalence of rare diseases
- > Orphan drugs in Europe

Getting involved /informed

- > Read the newsletter
- > Read OJRD [4]
- > Register your activity

Thank you for your attention

